ClinicalTrials.Veeva

Menu

Mitochondrial Diseases - Long-read Genome and Transcriptome Sequencing in Cases Unresolved After Short-read Genomics

U

University Hospital Tuebingen

Status

Completed

Conditions

Genetic Predisposition
Rare Diseases

Treatments

Genetic: Next Generation Sequencing (NGS)

Study type

Interventional

Funder types

Other

Identifiers

NCT03962452
MiDiSeq

Details and patient eligibility

About

The MiDiSeq project will enroll 20 unresolved index patients with suspected mitochondrial disease prioritized for genomic analysis.

Full description

In the MiDiSeq (monocentric, prospective, open-label diagnostic) project, patients with suspected mitochondrial disease prioritized for i) high a priori probability for a genetic basis (e.g. positive family history) as well as availability of (ii) fibroblast cell lines with a biochemically defined phenotype, (iii) parental samples, (iv) short read whole genome and transcriptome datasets and (v) optional additional metabolomics and proteomics data.

The following questions will be leading the project:

i) to systematically benchmark different sequencing technologies to detect genetic and epigenetic variation and their impact on gene regulation.

(ii) to further develop algorithms for integrative analyses of different 'omics datasets.

(iii) to expand the analysis from coding Single-Nucleotide Variants (SNVs) and regulatory mutations to structural variants (SVs), repeat expansions and contractions, low complexity regions and epigenetic signatures.

(iv) to identify novel alterations and disease mechanisms. (v) to gain fundamental new insights into disease mechanisms and cellular biology.

(vi) to improve genetic diagnostics of future rare disease patients and to evaluate personalized therapeutic options.

Enrollment

20 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

Unclear diagnosis Suspected genetic cause of the disease

Exclusion criteria

Missing informed consent of the patient/ legal guardian

Trial design

Primary purpose

Basic Science

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

20 participants in 1 patient group

Mitochondrial disease
Other group
Description:
Unresolved index patients with suspected mitochondrial disease
Treatment:
Genetic: Next Generation Sequencing (NGS)

Trial contacts and locations

1

Loading...

Central trial contact

Olaf Rieß, Prof. Dr.; Tobias Haack, Dr.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems